Anticoagulant Market, By Drug Class (Novel Oral Anticoagulants (NOACs), Heparin and Low-molecular- weight Heparin(LMWH), and Vitamin K Antagonist), By Application (Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis (DVT), Pulmonary Embolism, and Other Applications), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Anticoagulants are a class of drugs that help prevent blood clots. They are commonly called blood thinners. They're given to people at a high risk of getting clots, to reduce the chances of developing serious conditions such as strokes and heart attack. Anticoagulants are commonly used to prevent and treat cardiovascular diseases (CVDs).
Market Dynamics:
Growing prevalence of chronic disease, rise in demand for anticoagulants, increase in focus on the development of novel anticoagulants, and growing geriatric population across the globe are major factors expected to drive growth of the global anticoagulant market.
For instance, in June 2022, Apotex Inc. announced the launch of APO-Apixaban tablets, Canada's first generic alternative to Eliquis. Apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots.
Moreover, in June 2021, the Food and Drug Administration (FDA) approved Pradaxa (dabigatran etexilate) oral pellets to treat children three months to 12 years old with venous thromboembolism. FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook